One lot of the company’s branded dextroamphetamine sulfate tablets is being removed from shelves nationwide due to a pharmacy receiving carbinoxamine maleate instead.
Azurity Pharmaceuticals Inc. has decided to voluntarily recall one lot of its branded dextroamphetamine sulfate tablets (30 mg) known as Zenzedi after receiving the news from a pharmacist in Nebraska that they had found tablets of carbinoxamine maleate, an antihistamine drug instead. Zenzedi is intended to treat the sleep disorder narcolepsy. The manufacturer sent recall notification letters to wholesale distributors on Jan. 4, arranging for the return of all recalled products at this particular supply chain level.
Patients who were to accidentally consume carbinoxamine could experience a multitude of different symptoms, including:
For patients diagnosed with attention deficit hyperactivity disorder (ADHD) and narcolepsy, consuming carbinoxamine could potentially lead to ongoing disability or death, particularly if they were to unknowingly use it and had planned on engaging in activities that normally require major alertness and focus.
The Zenzedi 30 mg tablets are light yellow and hexagonally shaped, with a “30” on one side and “MIA” on the other side. They are distributed in a white bottle containing black writing and “30 mg” highlighted yellow. On the other hand, the carbinoxamine maleate tablets (USP, 4 mg) are white and round with imprints of “GL” on one side and “211” on the other side.
Consumers who purchased this particular product that is being recalled should stop using and return it to the place of purchase.
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing. Azurity. January 24, 2024. Accessed January 29, 2024. https://azurity.com/azurity-pharmaceuticals-inc-issues-voluntary-nationwide-recall-of-zenzedi-dextroamphetamine-sulfate-tablets-usp-30-mg-due-to-a-mislabeled-package-during-manufacturing/